|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for GRM2 |
 Gene summary |
| Basic gene Info. | Gene symbol | GRM2 |
| Gene name | glutamate receptor, metabotropic 2 | |
| Synonyms | GLUR2|GPRC1B|MGLUR2|mGlu2 | |
| Cytomap | UCSC genome browser: 3p21.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000839.3, NM_001130063.1, | |
| Description | glutamate metabotropic receptor 2glutamate receptor homologmetabotropic glutamate receptor 2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604099 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000164082 | ||
| HPRD : 04977 | ||
| Vega : OTTHUMG00000156902 | ||
| Protein | UniProt: Q14416 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GRM2 | |
| BioGPS: 2912 | ||
| Pathway | NCI Pathway Interaction Database: GRM2 | |
| KEGG: GRM2 | ||
| REACTOME: GRM2 | ||
| Pathway Commons: GRM2 | ||
| Context | iHOP: GRM2 | |
| ligand binding site mutation search in PubMed: GRM2 | ||
| UCL Cancer Institute: GRM2 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for GRM2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Y216 | E218K | STAD | 2 | A166 | S164G | SKCM | 1 | Y216 | D215Y | THCA | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for GRM2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | Y216 | E218K | -1.2190024 | A166 | S164G | -1.1384016 | Y216 | D215Y | -0.84786061 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for GRM2 from PDB |
| PDB ID | PDB title | PDB structure | 4XAS | mGluR2 ECD ligand complex |  |
| Top |
| Differential gene expression and gene-gene network for GRM2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for GRM2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0036341 | Schizophrenia | 14 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0014556 | Epilepsy, Temporal Lobe | 2 | Biomarker |
| umls:C0236733 | Amphetamine-Related Disorders | 1 | Biomarker |
| umls:C0033941 | Psychoses, Substance-Induced | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for GRM2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Investigational | DB05096 | LY2140023 | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of GRM2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 40F | (1S,2S,5R,6S)-2-AMINOBICYCLO[3.1.0]HEXANE-2,6- DICARBOXYLIC ACID | 4xaq | A | A166 Y216 | 40F | (1S,2S,5R,6S)-2-AMINOBICYCLO[3.1.0]HEXANE-2,6- DICARBOXYLIC ACID | 4xaq | B | A166 Y216 | 40H | (1R,4S,5S,6S)-4-AMINOSPIRO[BICYCLO[3.1.0]HEXANE-2,1'- CYCLOPROPANE]-4,6-DICARBOXYLIC ACID | 4xas | A | A166 Y216 | 40H | (1R,4S,5S,6S)-4-AMINOSPIRO[BICYCLO[3.1.0]HEXANE-2,1'- CYCLOPROPANE]-4,6-DICARBOXYLIC ACID | 4xas | B | A166 Y216 | GGL | L-GLUTAMIC ACID RESIDUE | 5cni | A | A166 Y216 | GGL | L-GLUTAMIC ACID RESIDUE | 5cni | B | A166 Y216 | 52Q | (1R,2S,4R,5R,6R)-2-AMINO-4-(1H-1,2,4-TRIAZOL-3- YLSULFANYL)BICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID | 5cnj | A | A166 Y216 | 52Q | (1R,2S,4R,5R,6R)-2-AMINO-4-(1H-1,2,4-TRIAZOL-3- YLSULFANYL)BICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID | 5cnj | B | A166 Y216 |
| Top |
| Conservation information for LBS of GRM2 |
| Multiple alignments for Q14416 in multiple species |
| LBS | AA sequence | # species | Species | A166 | PQISYASTSAK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D295 | TWVASDGWGAL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E273 | LFTRSEDAREL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G296 | WVASDGWGALE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K377 | FEQESKIMFVV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R271 | AVLFTRSEDAR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R57 | PVNEHRGIQRL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R61 | HRGIQRLEAML | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S143 | GVIGGSYSDVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S145 | IGGSYSDVSIQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S167 | QISYASTSAKL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S272 | VLFTRSEDARE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T168 | ISYASTSAKLS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T270 | VAVLFTRSEDA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y144 | VIGGSYSDVSI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y216 | ASEGDYGETGI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |